Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data
June 06 2019 - 8:45AM
Business Wire
DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today
announced a collaboration to enable a direct exchange of CGM data
from Dexcom with insulin data from InPen™ into both companies’
software applications. This agreement is the first of its kind and
paves the way for advanced diabetes decision support, an important
tool for insulin users.
Dexcom and Companion Medical are working together to develop a
seamless data transfer of both insulin and glucose information.
This collaboration enables both companies to offer advanced
features and algorithms to improve in-the-moment decisions for
those managing their diabetes with multiple daily injections.
Advanced decision support requires multiple inputs, including
current glucose, glucose trend, carbohydrate intake, accurate
insulin dosing and insulin-on-board.
“Dexcom is committed to helping people make better therapy
decisions based on their glucose levels, and Companion is committed
to helping people make better insulin dosing decisions. These
decisions are synchronous to the person living with diabetes which
provides a compelling opportunity for our teams to work together,”
said Steve Pacelli, EVP of Strategy and Corporate Development at
Dexcom.
“We are pleased to be partnering with Dexcom on this important
mission. Improving outcomes for people on multiple daily injections
requires bringing together the two critical factors of diabetes
management -- glucose and insulin -- in real-time. We are the first
two companies with the technology capable of providing an
integrated solution," said Sean Saint, CEO of Companion
Medical.
As a first step in this collaboration, Dexcom and Companion
Medical will enable InPen users to display long-acting and
rapid-acting insulin data in the Dexcom CLARITY Diabetes Management
Software. Dexcom CGM data is currently available in the Companion
Medical Insights by InPen report. This integration enables health
care providers to access a combined, comprehensive view of a
patient’s therapy plan, increasing the effectiveness of how and
when patients should dose and paving the way for improved and
transparent treatment decisions.
The InPen/CLARITY report integration will be launched and
available for preview at the upcoming American Diabetes Association
Conference in San Francisco. Both companies are actively developing
their real-time integrated systems.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated
to helping people better manage their diabetes by developing and
marketing continuous glucose monitoring (CGM) products and tools
for adult and pediatric people with diabetes. With exceptional
performance, comfort and lifestyle flexibility at the heart of its
technology, users have consistently ranked DexCom highest
in customer satisfaction and loyalty. For more information on the
Dexcom CGM, visit www.dexcom.com.
About Companion Medical, Inc.
Companion Medical is a leader in the development of advanced
technology to improve diabetes care. InPen™, the first and only
FDA-cleared smart insulin pen, combines an innovative diabetes
management app with a Bluetooth® enabled pen injector to simplify
the constant tracking, monitoring and calculating required for
insulin therapy. InPen addresses many of the issues that people
living with diabetes face on a daily basis, including missed
insulin doses, miscalculated insulin doses and insulin
stacking.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190606005174/en/
Dexcom Investor Contact:Steve Pacelli, 858-200-0200
Dexcom Press Contact:James McIntosh, 619-884-2118
Companion Medical Media Contact:Steve
Lamarpr@companionmedical.com(858) 522-0252CompanionMedical.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2023 to Sep 2024